MedPath

Prednisone

Generic Name
Prednisone
Brand Names
Deltasone, Rayos, Winpred
Drug Type
Small Molecule
Chemical Formula
C21H26O5
CAS Number
53-03-2
Unique Ingredient Identifier
VB0R961HZT
Background

A synthetic anti-inflammatory glucocorticoid derived from cortisone. It is biologically inert and converted to prednisolone in the liver.

Prednisone was granted FDA approval on 21 February 1955.

Indication

Prednisone is indicated as an anti-inflammatory or immunosuppressive drug for allergic, dermatologic, gastrointestinal, hematologic, ophthalmologic, nervous system, renal, respiratory, rheumatologic, infectious, endocrine, or neoplastic conditions as well as in organ transplant.

Associated Conditions
Acne Vulgaris, Acute Exacerbation of Chronic Obstructive Pulmonary Disease, Acute Gouty Arthritis, Acute Leukemia, Aggressive Lymphoma, Allergic Bronchopulmonary Aspergillosis, Allergic Conjunctivitis (AC), Allergic Rhinitis (AR), Allergic corneal marginal ulcers, Alveolitis, Extrinsic Allergic, Ankylosing Spondylitis (AS), Aspiration Pneumonitis, Asthma, Atopic Dermatitis, Autoimmune Hepatitis, Bell's Palsy, Berylliosis, Bullous dermatitis herpetiformis, Chorioretinitis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Contact Dermatitis, Disseminated tuberculosis, Drug hypersensitivity reaction, Edema of the cerebrum, Epicondylitis, Erythroblastopenia, Giant Cell Arteritis (GCA), Hypercalcemia of Malignancy, Idiopathic Pulmonary Fibrosis (IPF), Immune Thrombocytopenia (ITP), Iridocyclitis, Iritis, Keratitis, Leukemias, Loeffler's syndrome, Lymphoma, Meningitis caused by Mycobacterium Tuberculosis, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Mycosis Fungoides (MF), Ocular Inflammation, Ophthalmia, Sympathetic, Optic Neuritis, Pain caused by Herpes zoster, Pemphigus, Pericarditis, Pneumocystis Jirovecii Pneumonia, Polymyalgia Rheumatica (PMR), Polymyositis, Posterior Uveitis, Primary adrenocortical insufficiency, Psoriatic Arthritis, Pure Red Cell Aplasia, Regional Enteritis, Relapsing Polychondritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Secondary adrenocortical insufficiency, Secondary thrombocytopenia, Serum Sickness, Severe Seborrheic Dermatitis, Sjogren's Syndrome (SS), Solid Organ Transplant Rejection, Stevens-Johnson Syndrome, Systemic Lupus Erythematosus, Takayasu Arteritis, Thyroid Eye Disease, Thyroiditis, Thyrotoxicosis, Trichinosis, Ulcerative Colitis, Uveitis, Vasculitis, Acquired immune hemolytic anemia, Acute Bursitis, Acute Crohn's Disease (CD), Acute Multiple sclerosis exacerbation, Acute rheumatic carditis, Anterior eye segment inflammation, Exfoliative erythroderma, Fulminating Tuberculosis, Idiopathic Bronchiolitis obliterans with organizing pneumonia, Idiopathic eosinophilic pneumonias, Non-suppurative Thyroiditis, Severe Psoriasis, Subacute Bursitis, Symptomatic Sarcoidosis, Synovitis of osteoarthritis, Systemic Dermatomyositis, Varicella-zoster virus acute retinal necrosis
Associated Therapies
Palliative Treatment
Clinical Trials
Related News

Combined Treatment of Methotrexate + Glucocorticoids Versus Glucocorticoids Alone in Patients With PM and DM

Phase 3
Completed
Conditions
Dermatomyositis
Polymyositis
Interventions
Drug: Prednisone
Drug: Methotrexate
First Posted Date
2008-04-02
Last Posted Date
2016-05-12
Lead Sponsor
Institute of Rheumatology, Prague
Target Recruit Count
31
Registration Number
NCT00651040
Locations
🇨🇿

Revmatologicky ustav, Prague, Czech Republic

A Study of an Experimental Chemotherapy Combination to Treat Hormone Refractory Prostate Cancer

Phase 2
Completed
Conditions
Prostate Cancer
Interventions
Drug: docetaxel
Drug: LY2181308 sodium
Drug: Prednisone
First Posted Date
2008-03-24
Last Posted Date
2019-04-03
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
154
Registration Number
NCT00642018
Locations
🇪🇸

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Pamplona, Spain

Study Evaluating 2 Dosing Regimens Of TRU-015 In Rheumatoid Arthritis

Phase 2
Terminated
Conditions
Arthritis, Rheumatoid
Interventions
Drug: TRU-015
Drug: Methylprednisolone
Drug: Prednisone
First Posted Date
2008-03-13
Last Posted Date
2013-03-11
Lead Sponsor
Pfizer
Target Recruit Count
222
Registration Number
NCT00634933
Locations
🇷🇸

Pfizer Investigational Site, Niska Banja, Serbia

Satraplatin and Prednisone to Treat Prostate Cancer

Phase 2
Completed
Conditions
Prostate Cancer
Genetic Polymorphism
Interventions
Drug: Satraplatin
Drug: prednisone
First Posted Date
2008-03-13
Last Posted Date
2018-10-02
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
24
Registration Number
NCT00634647
Locations
🇺🇸

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

🇺🇸

Associates in Oncology and Hematology, Rockville, Maryland, United States

A Phase I/II Trial of VR-CHOP in Lymphoma Patients

Phase 1
Completed
Conditions
Follicular Lymphoma
Lymphoma, B-Cell
Interventions
Drug: Bortezomib
Biological: Rituximab
Drug: Doxorubicin
Drug: Cyclophosphamide
Drug: Vincristine
Drug: Prednisone
First Posted Date
2008-03-12
Last Posted Date
2016-10-27
Lead Sponsor
Emory University
Target Recruit Count
37
Registration Number
NCT00634179
Locations
🇺🇸

Emory University Winship Cancer Institute, Atlanta, Georgia, United States

Mitoxantrone, Etoposide, and Vinorelbine As Second-Line Therapy in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy

Phase 2
Completed
Conditions
Prostate Cancer
First Posted Date
2008-03-03
Last Posted Date
2011-05-16
Lead Sponsor
Groupe D'Etude des Tumeurs Uro-Genitales
Target Recruit Count
90
Registration Number
NCT00627354
Locations
🇫🇷

Centre Regional Francois Baclesse, Caen, France

Azathioprine Versus Placebo in Pemphigus Vulgaris Treated With Prednisolone

Phase 2
Completed
Conditions
Pemphigus Vulgaris
Interventions
Drug: Azathioprine
Drug: Prednisone
Drug: Placebo
First Posted Date
2008-02-29
Last Posted Date
2010-11-30
Lead Sponsor
Tehran University of Medical Sciences
Target Recruit Count
48
Registration Number
NCT00626678
Locations
🇮🇷

Department of Dermatology, Tehran University of Medical Sciences, Tehran, Iran, Islamic Republic of

Combination Chemotherapy Based on Risk of Relapse in Treating Young Patients With Acute Lymphoblastic Leukemia

First Posted Date
2008-02-13
Last Posted Date
2015-01-14
Lead Sponsor
Associazione Italiana Ematologia Oncologia Pediatrica
Target Recruit Count
2039
Registration Number
NCT00613457

Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma

Phase 3
Active, not recruiting
Conditions
Multiple Myeloma
Interventions
Other: Laboratory Biomarker Analysis
Drug: Melphalan
Drug: Lenalidomide
Drug: Prednisone
Other: Quality-of-Life Assessment
Drug: Thalidomide
First Posted Date
2008-01-28
Last Posted Date
2024-12-27
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
306
Registration Number
NCT00602641
Locations
🇺🇸

Illinois CancerCare-Peoria, Peoria, Illinois, United States

🇺🇸

Methodist Medical Center of Illinois, Peoria, Illinois, United States

🇺🇸

OSF Saint Francis Medical Center, Peoria, Illinois, United States

and more 387 locations

Neoadjuvant Docetaxel on Newly Diagnosed Intermediate and High Grade Cancer of the Prostate

Phase 2
Withdrawn
Conditions
Stage II Prostate Cancer
Adenocarcinoma of the Prostate
Stage I Prostate Cancer
Prostate Cancer
Interventions
Drug: Docetaxel
Drug: Prednisone
First Posted Date
2008-01-23
Last Posted Date
2016-12-08
Lead Sponsor
John P. Fruehauf
Registration Number
NCT00598858
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy